Mutual of America Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-7,651
| Closed | -$219K | – | 1465 |
|
|
2024
Q2 | $219K | Sell |
7,651
-349
| -4% | -$9.93K | ﹤0.01% | 1379 |
|
|
2024
Q1 | $234K | Sell |
8,000
-128
| -2% | -$3.93K | ﹤0.01% | 1378 |
|
|
2023
Q4 | $274K | Sell |
8,128
-8
| -0.1% | -$234 | ﹤0.01% | 1333 |
|
|
2023
Q3 | $250K | Sell |
8,136
-847
| -9% | -$30.5K | ﹤0.01% | 1306 |
|
|
2023
Q2 | $360K | Sell |
8,983
-465
| -5% | -$19.2K | ﹤0.01% | 1233 |
|
|
2023
Q1 | $386K | Sell |
9,448
-168
| -2% | -$6.68K | ﹤0.01% | 1197 |
|
|
2022
Q4 | $371K | Buy |
9,616
+499
| +5% | +$24.3K | ﹤0.01% | 1203 |
|
|
2022
Q3 | $485K | Buy |
9,117
+1,486
| +19% | +$82.6K | 0.01% | 1131 |
|
|
2022
Q2 | $445K | Buy |
7,631
+1,212
| +19% | +$79.4K | 0.01% | 1124 |
|
|
2022
Q1 | $490K | Buy |
6,419
+333
| +5% | +$22.2K | 0.01% | 1119 |
|
|
2021
Q4 | $366K | Buy |
6,086
+158
| +3% | +$8.71K | ﹤0.01% | 1187 |
|
|
2021
Q3 | $332K | Sell |
5,928
-331
| -5% | -$19.1K | ﹤0.01% | 1203 |
|
|
2021
Q2 | $380K | Buy |
6,259
+401
| +7% | +$25.4K | ﹤0.01% | 1209 |
|
|
2021
Q1 | $411K | Buy |
5,858
+445
| +8% | +$31.8K | ﹤0.01% | 1173 |
|
|
2020
Q4 | $324K | Buy |
5,413
+248
| +5% | +$14.5K | ﹤0.01% | 1183 |
|
|
2020
Q3 | $311K | Buy |
5,165
+3,112
| +152% | +$181K | ﹤0.01% | 1137 |
|
|
2020
Q2 | $108K | Buy |
2,053
+209
| +11% | +$8.73K | ﹤0.01% | 1184 |
|
|
2020
Q1 | $62K | Buy |
1,844
+323
| +21% | +$13.4K | ﹤0.01% | 1239 |
|
|
2019
Q4 | $69K | Sell |
1,521
-16
| -1% | -$680 | ﹤0.01% | 1268 |
|
|
2019
Q3 | $59K | Buy |
+1,537
| New | +$61.3K | ﹤0.01% | 1300 |
|
|
2019
Q2 | – | Sell |
-88,124
| Closed | -$3.35M | – | 1706 |
|
|
2019
Q1 | $3.35M | Sell |
88,124
-47,655
| -35% | -$1.86M | 0.05% | 606 |
|
|
2018
Q4 | $5.84M | Sell |
135,779
-11,289
| -8% | -$527K | 0.1% | 260 |
|
|
2018
Q3 | $7.23M | Sell |
147,068
-8,486
| -5% | -$367K | 0.1% | 244 |
|
|
2018
Q2 | $4.99M | Buy |
155,554
+20,606
| +15% | +$711K | 0.07% | 394 |
|
|
2018
Q1 | $4.2M | Sell |
134,948
-17,909
| -12% | -$638K | 0.07% | 476 |
|
|
2017
Q4 | $6.98M | Buy |
152,857
+1,779
| +1% | +$70.5K | 0.11% | 230 |
|
|
2017
Q3 | $5.67M | Buy |
151,078
+90,416
| +149% | +$3.64M | 0.09% | 296 |
|
|
2017
Q2 | $2.89M | Sell |
60,662
-1,802
| -3% | -$83.6K | 0.05% | 637 |
|
|
2017
Q1 | $2.85M | Buy |
62,464
+30,526
| +96% | +$1.32M | 0.05% | 637 |
|
|
2016
Q4 | $1.03M | Sell |
31,938
-160
| -0.5% | -$5.34K | 0.02% | 1027 |
|
|
2016
Q3 | $1.1M | Hold |
32,098
| – | – | 0.02% | 1000 |
|
|
2016
Q2 | $1.08M | Buy |
32,098
+8,000
| +33% | +$393K | 0.02% | 990 |
|
|
2016
Q1 | $1.28M | Sell |
24,098
-100
| -0.4% | -$5.85K | 0.03% | 886 |
|
|
2015
Q4 | $1.86M | Buy |
24,198
+142
| +0.6% | +$8.04K | 0.04% | 718 |
|
|
2015
Q3 | $989K | Hold |
24,056
| – | – | 0.02% | 982 |
|
|
2015
Q2 | $1.7M | Hold |
24,056
| – | – | 0.04% | 790 |
|
|
2015
Q1 | $2.14M | Sell |
24,056
-690
| -3% | -$70K | 0.05% | 690 |
|
|
2014
Q4 | $2.19M | Buy |
+24,746
| New | +$2.34M | 0.05% | 663 |
|
Other funds holding PCRX
DPCM
Mutual of America Capital Management's PCRX Position: Q3 2024 in Review
Mutual of America Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 7,651 shares — an estimated $219K sold.
Mutual of America Capital Management first reported a position in PCRX in Q4 2014 and held it in 38 quarters. The position peaked at $7.23M in Q3 2018. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.
- Mutual of America Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
- Mutual of America Capital Management sold 7,651 Pacira BioSciences shares in Q3 2024, an estimated $219K.
- Mutual of America Capital Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 38 quarters.
- Mutual of America Capital Management's Pacira BioSciences position peaked at $7.23M in Q3 2018.
- 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.
Based on Mutual of America Capital Management's 13F filing for Q3 2024, filed 6 Nov 2024.